Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 10/20 | 0.60 |
| ▸ | MMP2 | P08253 | 10/20 | 0.60 |
| ▸ | MMP9 | P14780 | 10/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | SNCA | P37840 | 2/20 | 0.54 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.53 |
| ▸ | TDP2 | O95551 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.50 |
| ▸ | TOP1 | P11387 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108071 | 1.00 | MMP1 (0.60) | MMP1MMP2MMP9MAPTALDH1A1 | |
| SCHEMBL8348365 | 0.89 | MMP1 (0.56) | MMP1MMP2MMP9MAPTALDH1A1 | |
| SCHEMBL13886110 | 0.89 | MMP1 (0.56) | MMP1MMP2MMP9MAPTALDH1A1 | |
| SCHEMBL108150 | 0.86 | MMP1 (0.82) | MMP1MMP2MMP9ALOX15SNCA | |
| SCHEMBL28295696 | 0.84 | TGM2 (0.56) | MMP1MMP2MMP9LMNAALOX15 | |
| SCHEMBL13886075 | 0.82 | ALDH1A1 (0.49) | MMP1MMP2MMP9MAPTALDH1A1 | |
| SCHEMBL109020 | 0.80 | ALOX15 (0.66) | MAPTALOX15SNCATOP1 | |
| SCHEMBL107966 | 0.80 | SNCA (0.56) | MMP1MMP2MMP9ALDH1A1ALOX15 | |
| SCHEMBL28817693 | 0.80 | MMP1 (0.91) | MMP1MMP2MMP9ALOX15SNCA | |
| SCHEMBL28083555 | 0.80 | MMP1 (0.91) | MMP1MMP2MMP9ALOX15SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008838-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PROTAMED INC (US) | 2017-01-12 | — | — | US | disclosed |
| US-9051253-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's | PROTEOTECH INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051253-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's | PROTEOTECH INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-8895554-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease | PROTEOTECH INC (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895554-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease | PROTEOTECH INC (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140288183-A1 | Compounds and Compositions for use a Modulators of Tau Aggregation and Alleviation of Tauopathies | PROTAMED, INC. | 2014-09-25 | — | — | US | disclosed |
| US-8754133-B2 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754133-B2 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2527315-B1 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease | PROTEOTECH INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20140038980-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | PROTAMED, INC. | 2014-02-06 | — | — | US | disclosed |
| US-7514583-B2 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | PROTEOTECH, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514583-B2 | bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis | PROTEOTECH, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090069432-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTEOTECH INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069432-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | PROTEOTECH INC. | 2009-03-12 | — | — | US | disclosed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | PROTAMED, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | PROTEOTECH INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288183-A1 | Compounds and Compositions for use a Modulators of Tau Aggregation and Alleviation of Tauopathies | PSEN2, PSEN1, MAPT | MMP1 3372/4885MMP2 3826/4885MMP9 3889/4885 |
| US-20070208087-A1 | Compounds, compositions and methods for the treatment of inflammatory diseases | NR1H2, NR1H3, NR1H4 | MMP1 2448/4885MMP2 3979/4885MMP9 3291/4885 |
| US-20170008838-A1 | COMPOUNDS AND COMPOSITIONS FOR USE AS MODULATORS OF TAU AGGREGATION AND ALLEVIATION OF TAUOPATHIES | PSEN2, PSEN1, MAPT | MMP1 3421/4885MMP2 3867/4885MMP9 3941/4885 |
| US-20070225362-A1 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis | IAPP, SNCA, APP | MMP1 2156/4885MMP2 1752/4885MMP9 4401/4885 |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | SNCA, PARK7, COMT | MMP1 4760/4885MMP2 4375/4885MMP9 4665/4885 |
| US-20140038980-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | IAPP, SNCA, APP | MMP1 3000/4885MMP2 2177/4885MMP9 4269/4885 |
| US-20090069432-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | IAPP, APP, SNCA | MMP1 2708/4885MMP2 1857/4885MMP9 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.